Coherus BioSciences (CHRS)
(Delayed Data from NSDQ)
$0.99 USD
-0.01 (-0.91%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $0.99 0.00 (-0.09%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Balance Sheet
Fiscal Year End for Coherus BioSciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 118 | 192 | 417 | 541 | 178 |
Receivables | 261 | 110 | 123 | 0 | 142 |
Notes Receivable | 0 | 0 | 0 | 157 | 0 |
Inventories | 63 | 39 | 38 | 44 | 10 |
Other Current Assets | 35 | 41 | 24 | 25 | 14 |
Total Current Assets | 476 | 381 | 602 | 767 | 343 |
Net Property & Equipment | 5 | 9 | 8 | 10 | 6 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 68 | 76 | 56 | 48 | 45 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 72 | 6 | 4 | 4 | 4 |
Deposits & Other Assets | 10 | 9 | 10 | 3 | 1 |
Total Assets | 630 | 481 | 679 | 842 | 409 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 35 | 12 | 16 | 15 | 26 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 297 | 127 | 149 | 127 | 87 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 4 | 2 |
Total Current Liabilities | 332 | 139 | 165 | 146 | 115 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 227 | 226 | 333 | 330 | 105 |
Long-Term Debt | 246 | 245 | 76 | 74 | 74 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 13 | 3 | 1 | 1 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 823 | 618 | 582 | 561 | 304 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,386 | 1,204 | 1,148 | 1,044 | 1,001 |
Retained Earnings | -1,580 | -1,342 | -1,050 | -763 | -895 |
Other Equity | 0 | 0 | 0 | 0 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -193 | -137 | 98 | 281 | 105 |
Total Liabilities & Shareholder's Equity | 630 | 481 | 679 | 842 | 409 |
Total Common Equity | -193 | -137 | 98 | 281 | 105 |
Shares Outstanding | 111.30 | 77.70 | 76.70 | 72.00 | 70.10 |
Book Value Per Share | -1.74 | -1.77 | 1.27 | 3.90 | 1.50 |
Fiscal Year End for Coherus BioSciences, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 159 | 260 | 118 | 131 | 145 |
Receivables | 314 | 284 | 261 | 217 | 141 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 62 | 62 | 63 | 67 | 64 |
Other Current Assets | 23 | 22 | 35 | 30 | 35 |
Total Current Assets | 558 | 627 | 476 | 444 | 385 |
Net Property & Equipment | 3 | 4 | 5 | 6 | 7 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 50 | 66 | 68 | 79 | 64 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 55 | 57 | 72 | 47 | 6 |
Deposits & Other Assets | 8 | 9 | 10 | 8 | 8 |
Total Assets | 675 | 764 | 630 | 584 | 470 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 77 | 38 | 35 | 37 | 29 |
Current Portion Long-Term Debt | 0 | 175 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 386 | 325 | 297 | 203 | 140 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 463 | 538 | 332 | 240 | 169 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 228 | 227 | 227 | 227 | 226 |
Long-Term Debt | 37 | 72 | 246 | 246 | 246 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 28 | 13 | 4 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 759 | 845 | 823 | 717 | 644 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,406 | 1,395 | 1,386 | 1,367 | 1,286 |
Retained Earnings | -1,490 | -1,477 | -1,580 | -1,500 | -1,460 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -84 | -82 | -193 | -134 | -175 |
Total Liabilities & Shareholder's Equity | 675 | 764 | 630 | 584 | 470 |
Total Common Equity | -84 | -82 | -193 | -134 | -175 |
Shares Outstanding | 114.70 | 113.50 | 111.30 | 94.40 | 80.50 |
Book Value Per Share | -0.73 | -0.72 | -1.74 | -1.42 | -2.17 |